Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
With mcap of 15m what are the competitors waiting for? (don't mind starting a rumour LOL)
Expect this to be way higher by year end!
GL.
Wow 3m knocked off mcap on 4k of sells!
I shud give up!
GL.
Over promised under delivered
Funny how they walk it down on manipulated sells and then its NT to buy even 500 quids worth!
GL.
The end of year is the main target, still on track with cash flow into mid next year. Looking forward to the next few months where she should hear some solid updates on product launch and price range.
Added some more ! More buys than sells?
Knicked from advfn Paul Hill PMH Capital ltd :
'Unlike the consumer world, commercialising break-through medical science can often be frustratingly slow, even for major innovations. Why?
Well simplistically, there's a natural inertia built into the healthcare system. Here doctors are inherently cautious and need time to familiarise themselves with & fully deploy the latest technology. Equally, US insurers & public bodies (Medicare & Medicaid) must also agree to pick up the costs. That is (hopefully) before the hockey-stick growth begins & the product ultimately becomes the industry's de facto standard.
Unfortunately however both of these factors have impacted the initial pace of adoption of Verici Dx’s best-of-breed kidney transplant diagnostic Tutivia. Consequently at today’s interims, management reduced their near term revenue projections, but reiterated that #VRCI’s mid 2024 cash runway should be unaffected thanks to higher research revenues.
Moreover, Tutivia test volumes are now accelerating, albeit from low levels, as more transplant centres come on stream. While, the company also expects to receive full Medicare reimbursement (re under Local Cover Determination) by Q1’24, which should similarly boost turnover.
On the R&D front, significant progress is being made here as well. With its unique pre-transplant diagnostic Clarava on track for commercial launch in Q4'23. Elsewhere, initial sales of its 3rd test Protega are slated for 2025, which aims to predict the risk of kidney fibrosis and long-term graft failure.
CEO Sara Barrington commenting: "The clinician response to our 1st product, Tutivia, following its commercial launch in Jan’23 clearly demonstrates how much they value the key benefits and recognise the strong differentiating features. We are also excited to have announced a 2nd successful product, Clarava following the recently completed clinical validation study showing excellent results. We also completed enrolment for the validation study on our 3rd product, Protega - which completes the end-to-end testing for the portfolio as we look ahead."
"Although the timing effects on early adoption are frustrating, we have been able to make savings in other areas and are focused on research collaborations to help build a solid platform for future growth. At the same time, we are continuing to deliver on our strategy of transforming kidney transplant patient outcomes, as we move further into commercialisation”.
So what does all this mean?
Well top level, given Tutivia's “outstanding clinician feedback” - I’m highly confident Verici Dx's suite of cutting edge kidney transplant diagnostics will eventually become a major success. Likewise providing the Board with several attractive options (both internal & external) to finance its growth trajectory for years ahead.'
GL.
Agree with the below, the fun was always going to kick off at the end of this year and into 2025. The foundations have been set and we won't be down here in 6 months time. I've topped up myself.
Clive they did the same on the last to spikes. Raised it then shut sellers out with NT to sell. Low liquidity.
More updates to come. $1.8m staff costs with only 2 in the sales team leaves questions re affordability for expansion with current revenue without further funding.
Why question funding when they have reiterated all covered until mid 2024?
Revenues should accelerate from here and a JV can't be ruled out imho.
GL.
Nice delayed 150k buy nulls the delayed sell.
Buys way out numbering sells yet way down.
May get more if one of my others perform.
GL.
Questioning how they are going to afford and maintain sales force growth to boost products and revenues.